Clinical trial
The ENCALM Trial: A Randomized, Double-blind, Placebo-controlled Monotherapy Trial to Evaluate the Efficacy and Safety of ENX-102 in Patients With Generalized Anxiety Disorder
NCT05749055 is registered in ClinicalTrials.gov with Engrail Therapeutics INC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The ENCALM Trial: A Randomized, Double-blind, Placebo-controlled Monotherapy Trial to Evaluate the Efficacy and Safety of ENX-102 in Patients With Generalized Anxiety Disorder
- Lead sponsor
- Engrail Therapeutics INC
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- July 3, 2023
- Completion date
- September 18, 2025
- Enrollment
- 252 (actual)
- Sites
- 32
Conditions
As the registry lists them; a condition with its own page is linked.